May 2004
Volume 45, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2004
Transpupillary Thermotherapy for the treatment of Choroidal Neovascular Membrane
Author Affiliations & Notes
  • C.J. Cole
    Ophthalmology Unit, Southend Hospital, Westcliffe on Sea, United Kingdom
  • R. Akash
    Ophthalmology Unit, Southend Hospital, Westcliffe on Sea, United Kingdom
  • R. Pearson
    Ophthalmology Unit, Southend Hospital, Westcliffe on Sea, United Kingdom
  • Footnotes
    Commercial Relationships  C.J. Cole, None; R. Akash, None; R. Pearson, None.
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 5125. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      C.J. Cole, R. Akash, R. Pearson; Transpupillary Thermotherapy for the treatment of Choroidal Neovascular Membrane . Invest. Ophthalmol. Vis. Sci. 2004;45(13):5125.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: to assess the effectiveness of transpupillary thermotherapy (TTT) for the treatment of classic and occult choroidal neovascularisation (CNV). Methods: A retrospective, case selective, trial of 38 patients with angiographically defined CNV secondary to age–related macular degeneration (ARMD) treated with diode laser (810nm) TTT. Laser power ranged from 181–1490 mW and laser spot size ranged from 0.5–3mm. Treatment was given for 60 seconds. Outcome was assessed at 6 weeks with Snellen Visual Acuity and fundus flourescein angiogram (FFA). and at 3 months with Snellen Visual Acuity. Results: 4 eyes were subfoveal classic, 23 were subfoveal occult and 11 were mixed subfoveal classic and occult. At 6/52 post treatment the vision improved in 3/38 (7.9%) patients, stabilised (+/– 1 line) in 22/38 (57.9%) patients, was mildy reduced (2–5 lines) in 7/38 (18.4%) patients and severely reduced (>5 lines) in 6/38 (15.8%) patients. Final recorded best visual acuity showed improvement in 3/38 (7.9%) patients, stabilisation 18/38 (47.4%), mild loss 6/38 (15.8%) and severe loss 11/38 (28.9%). In all eyes the mean size of the CNV was 6.82mm2 but ranged from 0.1–26.84mm2. At six weeks post treatment the area of CNV was smaller on FFA in 10/30 (26.3%) and was larger in 10 (26.3%) patients, post treatment FFA results were not repeated on 18 patients, 11 of these patients (26.3%) were left with an atrophic or disciform scar clinically. There were no significant differences between classic and occult membranes. Conclusions: TTT is a treatment for CNV. There is stabilisation or improvement of vision in 21/38 (55.3 %) of patients. Further randomised controlled trials are required.

Keywords: retina • laser 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×